Lopinavir / Ritonavir: 5 agencies, 2002–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused lopinavir / ritonavir: all 7 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 18.4 years separate the first record, 1 May 2002 at PHARMAC (New Zealand), from the most recent, 7 Oct 2020 at HAS (France).
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
3 distinct indication wordings are recorded for lopinavir / ritonavir by the agencies that label one in English (AWMSG and SMC).
PHARMAC (New Zealand) was first to assess lopinavir / ritonavir, on 1 May 2002; SMC (Scotland) did not open a file until 12 Feb 2018 — an unusually long tail of 15.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
3 of the 5 agencies here assessed lopinavir / ritonavir more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed lopinavir / ritonavir.
The full ledger for lopinavir / ritonavir reads 7 recommended, 5 other and 2 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 7 Oct 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| SMC (Scotland) | 12 Feb 2018 | in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years. | accepted | source |
| AWMSG (Wales) | 21 Feb 2008 | Treatment of HIV-1 infected adults and children above the age of 2 years, in combination with other antiretroviral agent… | outside AWMSG criteria | source |
| TLV (Sweden) | 25 Aug 2006 | Ny beredning av Kaletra in i förmånerna | general subsidy | source |
| PHARMAC (New Zealand) | 1 May 2002 | HIV infection (salvage treatment only) | PTAC advice: High · decision reached | source |
9 further decisions for lopinavir / ritonavir, across 3 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 14 decisions for lopinavir / ritonavir from 5 agencies, 2002 to 2020. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.